Mohamed Ebied

Mohamed Ebied is an experienced professional in strategy and business development, currently serving as Head of Strategy & BD at Proteinea since September 2023. Prior to this role, Mohamed was a Senior Associate, Strategy at Proteovant Therapeutics from April 2021 to August 2023, a position held after the acquisition by SK Life Sciences. Earlier in the career, Mohamed worked at ClearView Healthcare Partners, where roles included Consultant, Senior Analyst, and Analyst from June 2019 to April 2021, along with a Summer Analyst position in 2018. Experience also includes an Investment Analyst role at General Biotechnologies, focusing on business development opportunities in small molecules, and participation in research fellowships at Harvard Medical School, where contributions included developing 3D-printed materials and a virtual reality system for neuroscience studies. Mohamed holds a Bachelor of Science in Bioengineering from Harvard University and completed the International Baccalaureate at The British International School, Cairo.